Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04150640 · ClinicalTrials.gov registry record · Phase 2
Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma
A Phase 2 study of Gastric Adenocarcinoma and Esophageal Adenocarcinoma, sponsored by University of Wisconsin, Madison.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
- 1
- Study location
NCT04150640 is a Phase 2 study of Gastric Adenocarcinoma and Esophageal Adenocarcinoma that is actively recruiting participants, run by University of Wisconsin, Madison. The registered enrollment target is 52 participants, below the 244-participant average among 47 other Gastric Adenocarcinoma trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04150640, a Phase 2 study of Gastric Adenocarcinoma and Esophageal Adenocarcinoma, is actively recruiting participants, sponsored by University of Wisconsin, Madison.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open label, phase II, multi-site trial evaluating the efficacy and safety of the combination of 5-FU, oxaliplatin, nal-IRI, and immunotherapy (plus trastuzumab for HER2-positive tumors) as first-line therapy for participants with advanced Esophageal and Gastric Adenocarcinoma (EGA). The investigators hypothesize that this drug combination will be better tolerated than current first-line chemotherapy combinations for this disease.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Trastuzumab
- DRUG Oxaliplatin
- DRUG 5-FU
- DRUG Nal-IRI
Study Locations (1)
Wisconsin
- University of Wisconsin Carbone Cancer Center - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2020-07-13 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04150640
The ClinicalTrials.gov registry entry for NCT04150640 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 244-participant average among 47 other Gastric Adenocarcinoma trials with a reported enrollment target (79% lower). The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Gastric Adenocarcinoma appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT04150640 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT04150640 about?
NCT04150640 is a clinical study titled "Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma". This is an open label, phase II, multi-site trial evaluating the efficacy and safety of the combination of 5-FU, oxaliplatin, nal-IRI, and immunotherapy (plus trastuzumab for HER2-positive tumors) as first-line therapy for participants with advanced Esophageal and Gastric Adenocarcinoma (EGA). The i...
What is the current status of trial NCT04150640?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2020-07-13. Estimated completion is 2027-12.
What conditions does trial NCT04150640 study?
This clinical trial studies the following conditions: Gastric Adenocarcinoma, Esophageal Adenocarcinoma.
What interventions are being tested in trial NCT04150640?
The interventions under investigation include: Pembrolizumab (DRUG), Trastuzumab (DRUG), Oxaliplatin (DRUG), 5-FU (DRUG), Nal-IRI (DRUG).
Who is sponsoring clinical trial NCT04150640?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04150640 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastric Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study
RECRUITING · Phase 2
-
Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer
RECRUITING · Phase 2
-
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
RECRUITING · Phase 2
-
A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology
RECRUITING · Phase 2
-
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.